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Skin epidermis is an active site of lipid synthesis. The
intercellular lipids of human stratum corneum (SC) are unique
in composition and quite different from the lipids found in
most biological membranes. The three major lipids in the SC
are free fatty acids, cholesterol and ceramides. Fatty acids
can be synthesized by keratinocytes de novo and, in addition,
need to be taken up from the circulation. The latter process
has been shown to be protein mediated, and several fatty acid
transporters are expressed in skin. Recent studies of transgenic
and knockout animal models for fatty acid transporters and
the identification of fatty acid transport protein 4 (FATP4 or
SLC27A4) mutations as causative for Ichthyosis Prematurity
Syndrome highlight the vital roles of fatty acid transport
and metabolism in skin homeostasis. This review provides
an overview of our current understanding of the role of fatty
acids and their transporters in cutaneous biology, including
their involvement in epidermal barrier generation and skin
inflammation.

Introduction
The skin is a complex and highly specialized organ serving multiple functions in the body, the main of which is to provide a barrier that prevents water loss and protects the body from adverse
environmental agents.1 This function is mediated exclusively by
the stratum corneum (SC)—the outermost layer of the epidermis, consisting of dead flattened keratinocytes embedded in a
lipid matrix, acting together as a “brick and mortar” system that
is difficult to penetrate. The lipids that constitute the extracellular lamellar matrix of the stratum corneum have a unique composition and exhibit distinctive properties.2 The major lipids of
the human SC are ceramides, cholesterol and fatty acids (FAs),
comprising approximately 50, 25 and 15% of the total lipid mass,
respectively.3 Interestingly, this mass composition reflects nearly
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equimolar quantities of ceramides, cholesterol and fatty acids, a
ratio that is imperative for normal lamellar membrane organization and epidermal barrier homeostasis.4,5 Both essential and
non-essential fatty acids play separate and critical roles in proper
skin function. In this review we will focus on the role of fatty
acids and their transporters in skin epidermal barrier functions
and disease.
Origin of Fatty Acids in the Epidermis
The epidermis is a very active site of lipid synthesis, exceeding
even the liver, kidney and gastrointestinal epithelia on a per
weight basis.6 Most of the FAs can be synthesized by keratinocytes de novo. FAs with carbon chains of up to C16 are synthesized by cytosolic fatty acid synthase (FAS). In normal human
epidermis, FAS is strongly expressed in the stratum granulosum
and moderately in the uppermost layer of the stratum spinosum,
suggesting that FA synthesis may increase during normal epidermal differentiation.7 Acute disruption of the epidermal barrier
stimulates FA synthesis, which is required for full recovery of
the barrier.8 A significant amount of the FAs produced by FAS,
as well as FAs taken up from diet, are further elongated into
very long chain FAs (C ≥18).9 The role of FA elongation in
epidermal function will be discussed in detail in the review by
Dr. Y. Uchida in this series. We will only mention that during cornification, short-chain FAs are replaced by long-chain,
highly saturated species, ranging from 14 to 28 carbons in
length. The majority are 20 carbons and longer, with 22–24
carbon lengths being the most abundant.3
However, not all fatty acids can be synthesized by keratinocytes, and not all that can be synthesized are produced in sufficient quantities. Research performed more than 80 years ago
show that essential fatty acid (EFA) deficiency leads to abnormalities in skin function, resulting in scaly dermatosis, permeability
of skin to water and hair loss.10 The human body can produce all
but two of the fatty acids it needs: linoleic acid (C18:2, n6) and
alpha-linolenic acid (C18:3, n3). In addition to these, nutritional
studies have revealed the existence of so called conditional EFAs,
such that the term EFA may be applied to over thirty omega-6
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and omega-3 polyunsaturated fatty acids.11 Skin is devoid of
delta-5 desaturase and so cannot directly convert gamma-linolenic acid to arachidonic acid. Thus, arachidonic acid (C20:4, n6)
in the epidermis is not of keratinocyte origin, but must be synthesized in the liver and transported into keratinocytes therefore
being an essential fatty acid for the skin. In addition to linoleic
and arachidonic acids, several long chain- and very long chainfatty acids (LCFA and VLCFA) were identified as EFAs for the
skin, and they also have to be translocated across the keratinocyte
plasma membrane.
Role of Fatty Acids in the Epidermis
FAs have multiple roles in the epidermis. They are found in
bound form in triglycerides, phospholipids, glycosylceramides
and ceramides, which are all playing a vital role in formation
of the epidermal permeability barrier.12 However, FAs in keratinocytes do not function only as building blocks. In addition to
their well known role in energy generation and storage, FAs can
be potent signaling molecules, activating the nuclear hormone
receptors peroxisome proliferators-activated receptors (Pars).13-15
Moreover, by acylation FAs may modify other signaling molecules, including Sonic hedgehog and Wnt,16 though the role
of such modifications in epidermal biology is not well studied.
There are a few recent studies concerning the role of protein palmitoylation in skin.17,18
EFAs are integral for normal stratum corneum structure
and function. Three acylceramide species unique to epidermis
contain linoleic acid esterifies to the terminal omega-hydroxyl
group of very long chain fatty acids (C ≥28–34). These ceramides are central to barrier function and essential for mammalian
survival.12 Substitution of the linoleic acid with non-essential
oleic acid, as in the case of EFA deficiency, will lead to barrier defects accompanied by proliferative epidermal changes.19
Atopic dermatitis and psoriasis, well known inflammatory skin
diseases, are characterized by changes in FA composition in
keratinocytes, indicating their possible involvement in modulating of inflammatory processes.20-25 Moreover, free FAs are
one of the major contributors to the acidic pH at the SC surface regulating permeability and antimicrobial barrier, inflammation and desquamation.26-28 And last, but not least, there is
accumulating evidence for the existence of an epidermis-specific
hepoxilin pathway for arachidonic acid utilization in keratinocytes, which is important for formation of functional epidermis.29-31 These genes include two lipoxygenases (ALOX12B,
ALOXE3), an ATP binding cassette transporter (ABCA12), a
potential receptor (ICHTHYIN ) and a gene coding for a protein
of the cytochrome P450 family (CYP4C22).29,32-34 Mutations in
these genes, as well as mutations in transglutaminase 1 (TG1),
have been reported as the most common cause of autosomal
recessive congenital ichthyosis (ARCI). However, 20–40% of
the patients have no mutations in the six known ARCI genes
suggesting that more genes are involved in this type of ichthyoses.30,35 The role of lipoxygenases in formation of the epidermal
barrier will be reviewed in details by Alan Brash in this series
of reviews.
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Transport of Fatty Acids to the Epidermis
There are still ongoing debates regarding the mechanisms by
which free FAs are transported across cell membranes. On the one
hand, due to the lipophilic nature of FAs, it has been proposed
that they may be passively transported through the lipid bilayer
by “flip-flop” diffusion. This mechanism does not involve any
protein mediators.36,37 On the other hand, many studies have provided considerable support for the protein-mediated entry of long
chain fatty acids.38 While the exact mechanism by which FAs are
preferentially transported into cells is not yet settled, apparently
both modes of FA uptake (diffusion or protein-dependant) may
coexist in mammalian cells. The preferential mode of transport
may depend on: (1) the nature of the membrane (plasma membrane organelle or vesicular membrane); (2) cell type (e.g., adiposities, neurons and keratinocytes may have different systems
for FA transport); and (3) functional state of the cell (e.g., resting, activated, proliferative or cancer cells of the same origin may
employ different mechanisms). Recently, a unified hypothesis for
the role of the lipid bilayer and proteins was proposed for transport of FA into brain cells.39 However, due to space limitations
we will not discuss the different models for fatty acid transport in
details, but rather refer to several comprehensive reviews which
cover this topic.38,40-43
There are several lines of evidence suggesting that keratinocytes must import fatty acids from extracutaneous sites. In addition to EFAs which by definition must be obtained from the diet,
eicosapentaenoic acid (C22:6, n3) and docosahexaenoic acid
(C20:5, n3) derived from dietary fish oil are incorporated into
epidermal lipids.44 Second, plant-derived fatty acids accumulate
in the epidermis in certain diseases states, such as in Résumé’s
disease.45 Third, studies have shown that systemically administered 14C-labelled FAs were delivered to the epidermis.46 Fourth,
inhibition of FA synthesis in the epidermis does not completely
block barrier recovery after acute disruption, indicating that several sources of fatty acids are available to the keratinocytes.5 And
finally, studies have shown the active uptake of FAs by keratinocytes, which is temperature sensitive, has saturable kinetics,
and can be reduced by prior treatment with try sin, indicating
protein-mediated FA uptake.47 The latter study demonstrated
that keratinocytes transport EFAs, i.e., linoleic acid and arachidonic acid, with higher specificity than for non-essential FA,
such as oleic acid (C18:1, n9). These transport preferences were
not shared with other cell types, such as hepatocytes and dermal
fibroblasts, which transport non-essential and essential FA with
similar kinetics. However, identity of the protein(s) responsible
for FA uptake in keratinocytes was not determined in this study.47
In recent years, a number of proteins have been identified
that in some way may facilitate the LCFA transport in mammalian cells. They include fatty acid translocase (CD36/
FAT),48 fatty acid transport proteins (FATPs),49 fatty acid binding proteins (FABPs),50,51 long chain fatty acid-CoA synthetics
(ACSLs),52 and acyl-CoA binding proteins (ACBPs).53 Despite
the fact that these proteins have a different tissue expression
pattern and subcellular localization, there are evidences to suggest that each of these transporters can independently increase
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FA uptake (see references above). In addition, it was proposed
that FA transport can occur through the combination of caveolin and CD36/FAT in conjunction with lipid rafts.54,55 Finally,
an unknown protein has been reported recently to be involved in
uptake of FAs by adipocytes.56
How proteins contribute to FA uptake is again highly controversial. It was proposed that FATPs and CD36/FAT are the only
real transporters directly involved in binding and transport of
FAs across membranes.57,58 Moreover, they may interact in such
a way that FA binds first to CD36, which subsequently deliver
the free FA to the FATPs.38 However, whether CD36/FAT and
FATPs are directly involved in the translocation process is not
clear. Alternatively, these transporters may be indirectly involved
in FA uptake by binding and creating high local concentrations
of free FAs in close proximity to the membrane, as for CD36/
FAT,59 or by vectorial acylation, as for FATPs.43
After translocation to cytosol almost all FAs need to be activated by esterification with coenzyme A (CoA) before they can
be utilized, a process which is catalyzed by a family of enzymes
called acyl-CoA synthetases.60 FATPs possess acyl-CoA synthetase activity, generally preferring 16–18 carbon FAs, but can also
activate FAs as long as 26 carbons.61-64 Activation of FAs into
CoA-forms diminish the intracellular pool of free FAs, thus creating a gradient across the membrane and enhancing influx of
extracellular FAs, a process called vectorial acylation.43,65,66 The
majority of the substrate (FA) and the end product (acyl-CoA)
of the enzymatic reaction do not exist free in the cytosol under
physiological conditions, but are rather bound to FABPs67 or
ACBPs.53 Interestingly, all proteins in this pathway have been
reported to mediate FA uptake, indicating the existence of tightly
regulated mechanisms controlling concentration of the free FAs
and the free acyl-CoA forms in the cytosol. Deficiency in ACSLs
or in FABPs will lead to accumulation of LCFAs in the cytosol
and indirectly decrease FA uptake. Deficiency in ACBPs will create local high concentration of free acyl-CoA, which may inhibit
further esterification and indirectly affect FA transport. In addition, both free LCFAs and free acyl-CoA are potent signaling
molecules which may regulate expression of genes involved in
lipid metabolism through activation of nuclear hormone receptors. Moreover, if present in high concentrations, free FAs will
lead to lipotoxicity and ultimately to cell death.60 It is clear therefore, that the ability to control FA uptake and concentration in
the cytosol is vital for cell functions and survival.
Surprisingly, taking into account the high rate of lipid synthesis in keratinocytes, only a few studies have been published
reporting differential expression of putative FA transporters in
epidermis and skin appendages.68-71 These studies have shown
that FATP1, -3, -4 and -6, along with CD36/FAT, are expressed
in adult murine epidermis. Interestingly, FATP1 and -3 were
expressed predominantly by keratinocytes, whereas FATP4 was
strongly expressed by sebaceous glands and FATP6 by hair follicle epithelium.70 As a result of permeability barrier disruption in
mice, increase in expression of FATP1 and -6 have been observed,
as well as robust increase in CD36 protein and mRNA.69,70
FATPs expression in humans was comparable to that in mice.
Experiments with primary human keratinocytes show that the
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major FATP expressed in culture was FATP4, and induction of
differentiation induced by high calcium conditions (1.2 mM Ca 2+)
results in approximately 50% reduction in the level of FATP4
protein. In marked contrast to human and mouse epidermis,
neither FATP1, -3 nor -6 were expressed in either undifferentiated or differentiated human keratinocytes.70 In another study,
in addition to FATPs and CD36/FAT, plasma-membrane FABPs
and fatty acyl-CoA synthetase have been reported at different
levels in undifferentiated and differentiated human keratinocyte
cultures, as well as in mouse epidermis.69
The crucial role for proteins in the efficient uptake of LCFAs
was highlighted by a number of mouse models with impaired
or enhanced FA transport. In the next section we will discuss
cutaneous manifestations in these models as well as clinical
skin abnormalities that occurs secondary to mutations in FA
transporters.
Role of Fatty Acid Transporters in Skin:
Mouse Models and Possible Clinical Involvement
Among the number of mouse models with defective FA metabolism72,73 we will in this review discuss only “classical” transporters
such as CD36/FAT, FABPs and FATPs.
CD36/FAT. CD36 is an integral transmembrane glycoprotein with molecular mass of 88 kea in its fully glycosylated form,
functioning as a scavenger receptor for oxidized low-density
lipoproteins with multiple function in different cell types.74
CD36 was proposed to be a crucial transporter for long-chain
fatty acids mediated through interaction with lipid rafts and
caveolin.54,55,75 It is expressed in tissues with high FA metabolism, including adipose tissue, heart and skeletal muscles.48,74
CD36 has been also reported to be weakly expressed in normal
epidermis, with increased expression after barrier disruption.70
However, CD36 knockout mice do not have any apparent skin
phenotype, while defective uptake and utilization of LCFA have
been reported in muscles and adipose tissues.76-78 Recent finding indicate that CD36 mediates uptake of LCFAs, VLCFAs
and cholesterol in the intestine.79,80 Interestingly, CD36 has four
palmitoylation sites on both N- and C-termini, and it was shown
that palmitoylation plays a crucial role in targeting CD36 to
lipid rafts, where it mediates its function.81 In humans, CD36
deficiency has a prevalence of 0.3–11%, with higher incidences
in Asian and African populations,82 while again a skin phenotype was not obvious.83 Apparently, CD36-mediated uptake
of FAs in keratinocytes can be easily compensated by other FA
transporters.
FABP5. FABPs can be divided into two main groups: those
associated with plasma membrane (FABP-pm) and with intracellular, cytoplasmic proteins (FABPc). So far, nine tissue-specific
cytoplasmic FABPs with molecular mass 14–15 kea have been
identified, including cytosolic epidermal FABP (FABP5, also
termed E-FABP or PA-FABP).67 In contrast, FABP-pm has a
higher molecular weight (43 kea) and seems to be identical to
mitochondrial aspartame aminotransferase.84 Overexpression of
FABP-pm in mammalian tissues can increase uptake of FAs,85
and in human keratinocytes induction of differentiation by high
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calcium reduced FABP-pm mRNA by 50%.69 However, whether
this finding is relevant to the regulation of FA uptake into keratinocytes was not studied. Another study have shown that antibodies directed against FABP-pm did not inhibit FA uptake in
human keratinocytes, but did inhibit its uptake in hepatocyte cell
line HepG2, indicating that FABP-pm is unlikely to be responsible for the bulk of transport activity in keratinocytes.47
More is known about FABP5 which is predominantly
expressed in keratinocytes, where it has been proposed to act as a
cellular lipid chaperone in keratinocytes homeostasis.86,87 FABP5
has been detected also in tongue and thymus epithelia, as well
as in mammary and adipose tissues, while it seems that FABP5
is the only FABP which is detected in epidermis.87-90 Compared
with other tissues active in lipid metabolism, human keratinocytes contain a surprisingly low amount of FABP5, and its specific
role in normal skin is not yet fully established. The amount of
FABP5 increases with keratinocyte differentiation and immunohistochemical studies have demonstrated that FABP5 expression
is strongest in stratum granulosum, where activity of rate limiting enzymes required for barrier formation is the highest.86,91-93
Overexpression of FABP5 is associated with highly hyper-proliferative skin conditions, such as psoriasis, atopic dermatitis and
basal and squamous cell carcinomas.94-96 It can be speculated that
FABP5 expression is increased in response to increased lipid traffic, which may be related to abnormal proliferation and differentiation of keratinocytes in such conditions.
The skin of FABP5 knockout mice appears normal at the
gross and histological level, but the water-barrier function of the
epidermis is altered in these mice.89,97 It was shown that FABP5
deletion results in impaired keratinocyte migration, suggesting a
connection between FABP5 and cell motility.98 The lack of obvious skin phenotype raises the possibility that other FABP member or even other FA transporters can compensate for FABP5
deficiency during development.
Recent study by Ogawa and collegues90 helps to clarify the
mechanism of FABP5 action in epidermis. It was shown that
FABP5 deletion affects keratinocyte differentiation, but not proliferation. Total FA content in FABP5-deficient epidermis was
decreased including decreased saturated, monounsaturated and
polyunsaturated FAs. Detailed examination revealed that linoleic
acid (C18:2, n6) was significantly decreased, while arachidonic
and linolenic acid content was unchanged. Furthermore, the
authors showed that a linoleic acid derivative, 13-hydroxyoctadecadienoic acid [13(S)-HODE], mediates keratinocyte differentiation by activating the NFkB pathway. Consequently,
FABP5 deletion will lead to decreased cellular linoleic acid and
13(S)-HODE contents, resulting in downregulation of NFkB
activity and decreased differentiation.90 Given the strong expression of FABP5 in hyperproliferative skin conditions, it can be
suggested that FABP5 may have a role in the pathogenesis of such
diseases through impaired metabolism of FAs and their derivates.
Except for hyperproliferation in keratinocytes, no other clinical conditions caused by either deficiency of overexpression of
FABP5 have been reported so far in humans.
FATP4. Recently, mutations in the FATP4 gene (also known as
SLC27A4) were identified as causative for Ichthyosis Prematurity
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Syndrome (IPS).99 IPS is a rare disorder of cornification belonging to the heterogeneous group of autosomal-recessive congenital
ichthyoses (ARCI).100,101 Ultrastructural investigation of the first
IPS patients identified in Norway supported the idea that this
was a distinct type of congenital ichthyosis, termed ichthyosis
congenita type IV.102 IPS has been described almost exclusively
in a region in the middle of Norway and Sweden where the estimated heterozygote carrier frequency is 1 in 50.103 Outside of this
region, only a few cases have been reported in other European
countries, including Germany, Finland, Italy, Denmark and
France, as well as in families from North Africa and Middle
East.99,104-107 IPS is characterized by the clinical triad of premature
birth, scaly erythroderma and neonatal asphyxia in combination
with pathognomonic ultrastructural findings, typically showing
lipid membrane packages in the granular and horny cells.102,104
The severe skin phenotype at birth significantly improves during the first weeks of life, and recovers into a lifelong non-scaly
ichthyosis with dermal atopic dermatitis-like inflammation and
severe itching (D. Khnykin et al. unpublished). Interestingly,
most of the Norwegian patients have extremely high numbers of
eosinophils in peripheral blood and very high serum-Age levels;
both are central to etiology of atopic disorders (D. Khnykin et al.
unpublished).
FATP4 knockout mice also show a dramatic skin phenotype,
together highlighting the importance of this transporter for skin
homeostasis.108,109
FATP4 belongs to the family of membrane associated FATPs
consisting of six members, designated FATP1-6.49 They are proposed to mediate the translocation of FAs from the extracellular
milieu into cells. However, not all members were able to complement FA uptake in yeast studies.110,111 In addition, all six proteins
have acyl-CoA synthetase activity and are able to activate LCFAs
and VLCFAs to their CoA hoisters for subsequent metabolism.49,112,113 The mechanism by which FATPs mediate FA uptake
is not well understood, and it remains to be determined whether
they participate in the physical translocation process or facilitate
transport by trapping, as CoA derivatives, fatty acids that enter
cells by diffusion.38,54,114,115
Several FATPs, including FATP4, are expressed in the epidermis,70 and animal models suggest that FATP4 plays an important role in skin homeostasis. FATP4 knockout mice die either
in utero116 or shortly after birth,108,109 showing disturbed epidermal barrier and hyperkeratosis resulting in very tight, thick skin
(wrinkle free phenotype). Given the well-known importance of
lipids to the epidermal barrier,2,117 it was reasonable to hypothesize that the absence of FATP4 led to abnormal lipid trafficking
and failed production of the lipids required to establish a proper
skin barrier. Indeed, FATP4 was shown to be expressed in the epidermis primarily in the granular and upper spinous layers where
epidermal barrier lipid synthesis is robust.109,118 Furthermore, analysis of epidermal lipid composition by mass spectrometry in the
absence of FATP4 showed an increase in the fraction of ceramides
with fatty acid moieties containing 24 or fewer carbon atoms, at
the expense of those containing 26 or more.109,118 Ceramides are
crucial for barrier formation2,12 so this change in creamed composition likely contributes to the barrier abnormalities. Studies

Dermato-Endocrinology	Volume 3 Issue 2

of dermal fibroblast cell lines established from FATP4 knockout
mice revealed that FATP4 is in fact a principal VLCFA acyl-CoA
synthetase in skin fibroblasts.63 However, mutant fibroblasts also
showed reduced uptake of LCFAs and a reduced level of long
chain polyunsaturated FAs. Taking into account that FATP4deficient cells also contain abnormal neutral lipid droplets, this
indicates that the metabolic abnormalities in these cells are likely
not limited only to VLCFAs.63 Despite the high expression of
FATP4 in other tissues, such as intestine and brain,112,119 it was
possible to rescue the lethal phenotype of FATP4 knockout mice
by keratinocyte-specific transgenic expression of FATP4, resulting
in viable and fertile mice with only mild skin and hair abnormalities.118 This suggests that the skin phenotype of FATP4 mutants
is indeed due to the absence of FATP4 from epidermis. No structural or functional defects in other tissues have been observed
in the transgene-rescued mutants that lack FATP4 expression
in non-epidermal tissues.118 Importantly, keratinocytes-specific
expression of FATP4 mutated in the acyl-CoA synthetase domain
did not rescue the skin phenotype, indicating that the ability of
FATP4 to activate fatty acids is a crucial for its function.118
Another strategy was chosen by Herrmann et al.120 who created mice with conditional FATP4 deficiency in the epidermis.
This mouse line displays distinct changes in the structure of the
epidermis and a compromised barrier function, but the phenotype was not nearly as severe as that seen in mutant neonates.120
Interestingly, IPS patients carrying mutations in FATP4 gene
show much more severe phenotype immediately after birth and
in neonatal period, and show a mild form of ichthyosis in later life
(see below). The explanation for this apparent difference could
be that in adult skin FATP4 is compensated by other FATPs. As
was discussed above, adult skin expresses several FATPs, including FATP1, -3, -4 and -6,70 and FATP1 and 3 are predominantly
expressed by keratinocytes. However, studies of embryonic
expression at day 18.5 revealed that FATP1 is not expressed in
epidermis, whereas expression of FATP4 was relatively increased
compared with expression in adult epidermis.70 It can be speculated therefore, that FATP4 is more critical for the generation
of the epidermal barrier and less important for its maintenance,
because after birth the other FATPs may partially compensate for
the deficiency of FATP4.
To gain insights into why the absence of FATP4 in utero
causes the severe skin defects in mice, gene expression profiling was used to search for significant changes at embryonic
day 15.5.121 This is the gestational age at which the wrinkle free
phenotype first becomes detectable in some but not all Fatp4
mutants; thus, the hope was that any changes observed would
be directly related to the absence of FATP4 rather than secondary to the abnormal skin phenotype. The results suggested that
there was premature expression of genes relevant to establishing
the barrier, and this was validated by the presence of a precocious
but incomplete skin barrier at E16.5 that never progressed into a
complete barrier.121 Four members of the epidermal growth factor
(EGF) family of ligands were also upregulated. This was associated with increased activation of the EGF receptor (EGFR) and
of at least one of its downstream effectors, signal transducer and
activator of transcription-3 (STAT3). Pharmacological studies
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in vivo with curcumin and AG1478, inhibitors of EGFR and/or
STAT3 signaling, showed that activation of EGFR and STAT3
caused suprabasal keratinocyte hyperproliferation and thickening, as well as precocious barrier formation.121 However, the lack
of skin wrinkles was not ameliorated, indicating that other signaling pathways must contribute to that aspect of the phenotype.
Despite these insights into the signaling pathways associated with
the skin defects, why the absence of FATP4 leads to their activation (i.e., to the overexpression of EGF-like ligands) is an important remaining question.
FATP4 deficient mice models showed a non redundant role for
FATP4 in epidermis, comparing with other tissues,122,123 indicating the unique, specific role of FATP4 in generation and maintenance of the skin barrier.
The FATP4 gene (also known as SLC27A4) consists of 1 noncoding and 12 coding exons, encoding a protein of 643 residues
with a predicted size of 71 kDa.124 FATP4 is highly conserved
among widely divergent species and contains an N-terminal
transmembrane (TM) region, an ER localization signal (ERx),
as well as two functioning domains: ATP/AMP motif, responsible for ATP binding and FATP/VLACS motif, possessing very
long chain acyl-CoA synthetase activity and contributing to fatty
acid transport.111 Molecular genetic analysis of DNA from members of 18 Scandinavian IPS patients revealed that they all were
either homozygous or compound heterozygous for a nonsense
mutation in exon 3 of the FATP4 gene, whereas a North African
patient and a patient from the Middle East were homozygous for
a splice site mutation in exon 5 and a missense mutation in exon
12, respectively.99 Two new mutation in the FATP4 gene leading
to IPS were identified recently: missense mutation c.1120C>T in
a highly conserved region of exon 8,107 and a homozygous A>G
mutation in exon 2 (c.1a>g) which leads to conversion of the initiation codon ATG to GTG (p.M1V) (Inhoff et al. in press).
All together, nine mutations in FATP4, affecting several
domains of FATP4 protein, have been found so far in IPS patients
worldwide. The most frequent mutation is located in exon 3.99
If the mRNA for this allele is translated it will produce truncated protein without any FA transport or acyl-CoA synthetase activity.111 Of interest, mutation in mouse Fatp4 leads to
generation of a protein containing the first 133 amino acids of
FATP4 fused to 50 amino acids encoded by retrotransposon
antisense RNA,108 which will also lack acyl-CoA synthetase
activity. However, the mice exhibit a much more severe, lethal
phenotype, which may be due to a higher surface to volume
ratio as compared with humans, leading to excess loss of water
through the skin.
The mechanism by which FATP4 deficiency leads to a defective barrier and skin inflammation is not known and is only
beginning to be elucidated. Some of the possible mechanisms are
shown in Figure 1.
It would be tempting to speculate that impaired acyl-CoA
synthetase activity is the major trait associated with IPS pathology. FATP4 carrying a mutated acyl-CoA domain is functionally inactive in vivo and not able to rescue the skin phenotype in
FATP4 deficient mice, indicating a critical role for FA esterification by FATP4 in skin barrier formation.118 Indeed, tissues from

Dermato-Endocrinology

57

Therefore, it cannot be excluded that altered arachidonic acid metabolism are directly involved in
the skin pathology observed in humans and mice
with FATP4 deficiency.
Given the highly purity nature of IPS, another
possible factor affecting the phenotype could be
related to regulation of skin pH. The changes in
stratum corneum pH may be due to accumulation of free FAs, generated both in epidermis
and sebaceous glands. Local changes in pH can
activate proteases and their receptors in inappropriate temporal and spatial patterns, leading to
inflammation and itching.125-127 One more family
of proteins which are expressed in epidermis and
are pH-sensitive is the transient receptor potential
(TRP) channel family. Members of this family has
been shown to be involved in the pathogenesis of
itch128-130 and in skin barrier formation, where it
regulates EGFR signaling.131
Figure 1. Possible mechanisms for involvement of FATP4 deficiency in skin barrier funcFinally, proinflammatory signals may be genertion and inflammation. Possible, but not yet proven pathways are indicated (?). See text
ated not only in epidermis but also in skin appendfor details.
ages. FATP4 is highly expressed in sebaceous
glands,70 and absence of its acyl-CoA synthetase
FATP4 deficient mice, as well as both human and mouse FATP4 activity may lead to accumulation of free fatty acids in sebodeficient fibroblasts, show a decreased activation and incorpo- cytes, as well as in keratinocytes. Sebum free FAs may enhance
ration of very VLCFAs into complex structural lipids.62,63,99 production and secretion of antimicrobial peptides, which in
Analysis of lipid composition from FATP4 deficient epidermis turn may stimulate production of proinflammatory cytokines
revealed deficiency of VLCFAs (C ≥26) in epidermal cerami- and chemokines by keratinocytes.132,133
des,109,118 which might affect barrier properties of the skin. But
Concluding Remarks
barrier function may not be the only aspect of the epidermis
affected by the lack of FATP4 activity. The inability of FATP4
to activate VLCFA and LCFA could lead to intracellular accu- Although the exact mechanism by which FAs are transported
mulation of free FAs in the cell, leading to ER-stress and activa- into keratinocytes remains unclear, studies of different FA
transporters demonstrate their unique and important roles in
tion of proinflammatory pathways.60
Mouse FATP4 shows considerable activity in the esterification the epidermis for maintaining skin barrier and keratinocyte
of arachidonic acid in uptake- and activation-studies in yeast.110,111 homeostasis. Animal models of FATP4 deficiency, as well as
Moreover, the level of arachidonic acid was almost 50% lower in human phenotype in IPS, have demonstrated a vital role for
FATP4 deficient fibroblasts compared to control cells, while the FATP4 in mammalian skin development and formation of epilevel of linoleic acid was unchanged.63 Arachidonic acid is a pre- thelial barrier. Pathomechanism of FATP4 deficiency in skin
cursor of potent pro- and anti-inflammatory eicosanoids, and it is still poorly understood and clarifying of specific pathways
appears that the 12(R)-lipoxygenase pathway of arachidonic acid affected by such deficiency may yield new insights for the role
utilization plays a critical role in epidermal barrier formation.30,31 of fatty acid metabolism in epidermal biology.
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